Advertisement

Germline Mutations in African American Men With Prostate Cancer: Incidence, Implications and Diagnostic Disparities

      Abstract

      Recent data suggests that African American men (AAM) with prostate cancer (PCa) exhibit genetic alterations in highly penetrant germline genes, as well as low penetrant single nucleotide polymorphisms. The importance of germline variants of uncertain significance (VUS) remain poorly elucidated and given the elevated rates of VUS in AAM compared to Caucasians with PCa, further studies are needed to facilitate potential reclassification of VUS. Ongoing efforts to include AAM in genomics research is of paramount importance in order to ensure applicability of discoveries across diverse populations and potentially reduce PCa disparities as we embark on the era of precision medicine.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel RL
        • Miller KD
        • Fuchs HE
        • et al.
        Cancer statistics, 2021.
        CA Cancer J Clin. 2021; 71: 7-33
        • DeSantis CE
        • Miller KD
        • Goding Sauer A
        • et al.
        Cancer statistics for African Americans, 2019.
        CA Cancer J Clin. 2019; 69: 211-233
        • Taksler GB
        • Keating NL
        • Cutler DM
        Explaining racial differences in prostate cancer mortality.
        Cancer. 2012; 118: 4280-4289
        • Yamoah K
        • Johnson MH
        • Choeurng V
        • et al.
        Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer.
        J Clin Oncol. 2015; 33: 2789-2796
        • Williams VL
        • Awasthi S
        • Fink AK
        • et al.
        African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 1989-2015.
        Cancer Med. 2018; 7: 2160-2171
        • Lewis DD
        • Cropp CD
        The impact of African ancestry on prostate cancer disparities in the Era of precision medicine.
        Genes (Basel). 2020; 11
        • Nagy R
        • Sweet K
        • Eng C
        Highly penetrant hereditary cancer syndromes.
        Oncogene. 2004; 23: 6445-6470
        • Mucci LA
        • Hjelmborg JB
        • Harris JR
        • et al.
        Familial risk and heritability of cancer among twins in nordic countries.
        JAMA. 2016; 315: 68-76
        • Pritchard CC
        • Mateo J
        • Walsh MF
        • et al.
        Inherited DNA-repair gene mutations in men with metastatic prostate cancer.
        N Engl J Med. 2016; 375: 443-453
        • Nicolosi P
        • Ledet E
        • Yang S
        • et al.
        Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines.
        JAMA Oncol. 2019; 5: 523-528
        • Mersch J
        • Jackson MA
        • Park M
        • et al.
        Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.
        Cancer. 2015; 121: 269-275
        • Haraldsdottir S
        • Hampel H
        • Wei L
        • et al.
        Prostate cancer incidence in males with Lynch syndrome.
        Genet Med. 2014; 16: 553-557
        • Giri VN
        • Obeid E
        • Gross L
        • et al.
        Inherited mutations in men undergoing multigene panel testing for prostate cancer: emerging implications for personalized prostate cancer genetic evaluation.
        JCO Precision Oncol. 2017; : 1-17
        • Agalliu I
        • Karlins E
        • Kwon EM
        • et al.
        Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer.
        Br J Cancer. 2007; 97: 826-831
        • Castro E
        • Goh C
        • Olmos D
        • et al.
        Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
        J Clin Oncol. 2013; 31: 1748-1757
        • Ryan S
        • Jenkins MA
        • Win AK
        Risk of prostate cancer in lynch syndrome: a systematic review and meta-analysis.
        Cancer Epidem Biomar. 2014; 23: 437-449
        • Raymond VM
        • Mukherjee B
        • Wang F
        • et al.
        Elevated risk of prostate cancer among men with Lynch syndrome.
        J Clin Oncol. 2013; 31: 1713-1718
        • Shang Z
        • Zhu S
        • Zhang H
        • et al.
        Germline homeobox B13 (HOXB13) G84E mutation and prostate cancer risk in European descendants: a meta-analysis of 24 213 cases and 73 631 controls.
        Eur Urol. 2013; 64: 173-176
      1. National Comprehensive Cancer Network. Prostate Cancer (Version 2.2021). https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed March 29, 2021

      2. National Comprehensive Cancer Network. Prostate Cancer Early Detection (1.2021). https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Accessed March 29, 2021

        • Carter HB
        • Helfand B
        • Mamawala M
        • et al.
        Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer.
        Eur Urol. 2019; 75: 743-749
        • Mateo J
        • Carreira S
        • Sandhu S
        • et al.
        DNA-repair defects and olaparib in metastatic prostate cancer.
        N Engl J Med. 2015; 373: 1697-1708
        • Abida W
        • Patnaik A
        • Campbell D
        • et al.
        Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration.
        J Clin Oncol. 2020; 38: 3763-3772
        • Mota JM
        • Barnett E
        • Nauseef JT
        • et al.
        Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations.
        JCO Precis Oncol. 2020; 4: 355-366
        • Tucker MD
        • Zhu J
        • Marin D
        • et al.
        Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
        Cancer Med. 2019; 8: 4644-4655
        • Rencsok EM
        • Bazzi LA
        • McKay RR
        • et al.
        Diversity of enrollment in prostate cancer clinical trials: current status and future directions.
        Cancer Epidemiol Biomarkers Prev. 2020; 29: 1374-1380
        • Spratt DE
        • Chan T
        • Waldron L
        • et al.
        Racial/ethnic disparities in genomic sequencing.
        JAMA Oncol. 2016; 2: 1070-1074
        • Peprah E
        • Xu H
        • Tekola-Ayele F
        • et al.
        Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease.
        Public Health Genomics. 2015; 18: 40-51
        • Martin AR
        • Kanai M
        • Kamatani Y
        • et al.
        Clinical use of current polygenic risk scores may exacerbate health disparities.
        Nat Genet. 2019; 51: 584-591
        • Benafif S
        • Kote-Jarai Z
        • Eeles RA
        • et al.
        A review of prostate cancer Genome-Wide Association Studies (GWAS).
        Cancer Epidemiol Biomarkers Prev. 2018; 27: 845-857
        • Han Y
        • Rand KA
        • Hazelett DJ
        • et al.
        Prostate cancer susceptibility in men of African ancestry at 8q24.
        J Natl Cancer Inst. 2016; 108: 1-5
        • Freedman ML
        • Haiman CA
        • Patterson N
        • et al.
        Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men.
        Proc Natl Acad Sci U S A. 2006; 103: 14068-14073
        • Amundadottir LT
        • Sulem P
        • Gudmundsson J
        • et al.
        A common variant associated with prostate cancer in European and African populations.
        Nat Genet. 2006; 38: 652-658
        • Bensen JT
        • Xu Z
        • Smith GJ
        • et al.
        Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans.
        Prostate. 2013; 73: 11-22
        • Jingwi EY
        • Abbas M
        • Ricks-Santi L
        • et al.
        Vitamin D receptor genetic polymorphisms are associated with PSA level, Gleason score and prostate cancer risk in African-American men.
        Anticancer Res. 2015; 35: 1549-1558
        • Rand KA
        • Rohland N
        • Tandon A
        • et al.
        Whole-exome sequencing of over 4100 men of African ancestry and prostate cancer risk.
        Hum Mol Genet. 2016; 25: 371-381
        • Nordstrom T
        • Aly M
        • Eklund M
        • et al.
        A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
        Eur Urol. 2014; 65: 1184-1190
        • Sipeky C
        • Talala KM
        • Tammela TLJ
        • et al.
        Prostate cancer risk prediction using a polygenic risk score.
        Sci Rep. 2020; 10: 17075
        • Castro E
        • Goh C
        • Olmos D
        • et al.
        Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
        J Clin Oncol. 2013; 31: 1748-1757
        • Na R
        • Zheng SL
        • Han M
        • et al.
        Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death.
        Eur Urol. 2017; 71: 740-747
        • Kwon DH
        • Borno HT
        • Cheng HH
        • et al.
        Ethnic disparities among men with prostate cancer undergoing germline testing.
        Urol Oncol. 2020; 38 (80 e81-80 e87)
        • Sartor O
        • Yang S
        • Ledet E
        • et al.
        Inherited DNA-repair gene mutations in African American men with prostate cancer.
        Oncotarget. 2020; 11: 440-442
        • Beebe-Dimmer JL
        • Zuhlke KA
        • Johnson AM
        • et al.
        Rare germline mutations in African American men diagnosed with early-onset prostate cancer.
        Prostate. 2018; 78: 321-326
        • Agalliu I
        • Karlins E
        • Kwon EM
        • et al.
        Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer.
        Br J Cancer. 2007; 97: 826-831
        • Petrovics G
        • Price DK
        • Lou H
        • et al.
        Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
        Prostate Cancer Prostatic Dis. 2019; 22: 406-410
        • Matejcic M
        • Patel Y
        • Lilyquist J
        • et al.
        Pathogenic variants in cancer predisposition genes and prostate cancer risk in men of African ancestry.
        JCO Precis Oncol. 2020; 4: 32-43
        • Robinson D
        • Van Allen EM
        • Wu YM
        • et al.
        Integrative clinical genomics of advanced prostate cancer.
        Cell. 2015; 162: 454
        • Darst BF
        • Dadaev T
        • Saunders E
        • et al.
        Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer.
        J Natl Cancer Inst. 2021; 113: 616-625
        • Horak P
        • Weischenfeldt J
        • von Amsberg G
        • et al.
        Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance.
        Cold Spring Harb Mol Case Stud. 2019; 5: 1-9
        • Wang Y
        • Dai B
        • Ye D
        CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis.
        Int J Clin Exp Med. 2015; 8: 15708-15715
        • Isaacs WB
        • Cooney KA
        • Xu J
        Updated insights into genetic contribution to prostate cancer predisposition: focus on HOXB13.
        Can J Urol. 2019; 26: 12-13
        • Xu J
        • Lange EM
        • Lu L
        • et al.
        HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG).
        Human Genetics. 2013; 132: 5-14
        • Raymond VM
        • Mukherjee B
        • Wang F
        • et al.
        Elevated risk of prostate cancer among men with Lynch syndrome.
        J Clin Oncol. 2013; 31: 1713-1718
        • Zhen JT
        • Syed J
        • Nguyen KA
        • et al.
        Genetic testing for hereditary prostate cancer: current status and limitations.
        Cancer. 2018; 124: 3105-3117
        • Ndugga-Kabuye MK
        • Issaka RB
        Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European.
        Fam Cancer. 2019; 18: 465-469
        • Bentley AR
        • Callier S
        • Rotimi CN
        Diversity and inclusion in genomic research: why the uneven progress?.
        J Community Genet. 2017; 8: 255-266
        • Gamble VN
        Under the shadow of Tuskegee: African Americans and health care.
        Am J Public Health. 1997; 87: 1773-1778
        • Buseh AG
        • Stevens PE
        • Millon-Underwood S
        • et al.
        Community leaders' perspectives on engaging African Americans in biobanks and other human genetics initiatives.
        J Community Genet. 2013; 4: 483-494
        • Ewing A
        • Thompson N
        • Ricks-Santi L
        Strategies for enrollment of African Americans into cancer genetic studies.
        J Cancer Educ. 2015; 30: 108-115
        • Suther S
        • Kiros GE
        Barriers to the use of genetic testing: a study of racial and ethnic disparities.
        Genet Med. 2009; 11: 655-662
        • McDonald JA
        • Vadaparampil S
        • Bowen D
        • et al.
        Intentions to donate to a biobank in a national sample of African Americans.
        Public Health Genomics. 2014; 17: 173-182
        • Diaz VA
        • Mainous 3rd, AG
        • McCall AA
        • et al.
        Factors affecting research participation in African American college students.
        Fam Med. 2008; 40: 46-51
      3. American Urological Association. AUA 2019 Annual Census.https://www.auanet.org/research/research-resources/aua-census/census-results. Published 2019. Accessed April 3, 2021.

        • Late M
        Minority, underrepresented groups working to bring diversity to research: All of Us partners engage communities.
        The Nation's Health. 2019; 48: 17
        • Ademuyiwa FO
        • Salyer P
        • Ma Y
        • et al.
        Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations.
        Breast Cancer Res Treat. 2019; 178: 151-159
        • Haiman CA
        • Chen GK
        • Blot WJ
        • et al.
        Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans.
        PLoS Genet. 2011; 7e1001387
        • Irizarry-Ramirez M
        • Kittles RA
        • Wang X
        • et al.
        Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men.
        Prostate. 2017; 77: 1118-1127
        • Murphy AB
        • Ukoli F
        • Freeman V
        • et al.
        8q24 risk alleles in West African and Caribbean men.
        Prostate. 2012; 72: 1366-1373
        • Xu J
        • Kibel AS
        • Hu JJ
        • et al.
        Prostate cancer risk associated loci in African Americans.
        Cancer Epidemiol Biomarkers Prev. 2009; 18: 2145-2149
        • Chung CC
        • Hsing AW
        • Edward Y
        • et al.
        A comprehensive resequence-analysis of 250 kb region of 8q24.21 in men of African ancestry.
        Prostate. 2014; 74: 579-589
        • Jasin M
        Homologous repair of DNA damage and tumorigenesis:the BRCA connection.
        Oncogene. 2002; 21: 8981-8993
        • Shiloh Y
        • Ziv Y
        The ATM protein kinase: regulating the cellular response to genotoxic stress, and more.
        Nat Rev Mol Cell Biol. 2013; 14: 197-210
        • Zhang F
        • Fan Q
        • Ren K
        • et al.
        PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
        Mol Cancer Res. 2009; 7: 1110
        • Stolarova L
        • Kleiblova P
        • Janatova M
        • et al.
        CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate.
        Cells. 2020; 9: 2675
        • Graham A
        Developmental patterning. The Hox code out on a limb.
        Curr Biol. 1994; 4: 1135-1137
        • Ewing CM
        • Ray AM
        • Lange EM
        • et al.
        Germline mutations in HOXB13 and prostate-cancer risk.
        N Engl J Med. 2012; 366: 141-149
        • Akbari MR
        • Trachtenberg J
        • Lee J
        • et al.
        Association between germline HOXB13 G84E mutation and risk of prostate cancer.
        J Natl Cancer Inst. 2012; 104: 1260-1262